One Program, Every Regulator
Global Regulatory
Strategy
A dozen regulators. One plan that survives all of them.
A dozen regulators. One plan that survives all of them.
Every regional regulatory decision constrains the others: an endpoint FDA accepts that PMDA questions, a comparator EMA expects that doubles your trial, a CMC change filed in one market that triggers variations in thirty. Run each region on its own and the contradictions compound. We embed senior leaders who plan the whole board at once, so the sequence is deliberate, the dossier stays coherent, and no market becomes a surprise. Sequencing starts from the frameworks themselves: review the regulatory pathways open in each market.
A dozen agencies, sequenced so each decision strengthens the next instead of contradicting it.
A global launch is not one event; it is a sequence of waves. The first approval sets the reference the rest of the world leans on, and how you order the waves decides your speed and your cost in every market after.
The first filing sets the reference price and the data package every later market leans on.
FDA, EMA, and PMDA. The first approvals set the reference price and anchor the data package every later market relies on. Where you file first, and second, shapes the entire rollout.
Canada, Australia, Switzerland, the UK, and the many authorities that lean on a reference approval. Reliance procedures can compress these timelines dramatically, but only if the dossier was built to feed them.
The next thirty-plus markets where the program's real economics are decided. Efficient sequencing turns a long tail into a coordinated rollout instead of thirty separate projects.
A global filing program lives or dies on its core dossier: the CTD content that stays identical everywhere, the regional layers that adapt cleanly, and the change control that keeps thirty markets from quietly diverging.
One source of truth, adapted per region, so a change in one market never breaks another.
The quality, nonclinical, and clinical content that must read identically in every market, maintained as one controlled baseline.
The interactions with each authority are not independent errands. Run as one campaign, each answer becomes evidence in the next conversation.
Asked in the right order, each agency's answer strengthens your position with the next. Asked carelessly, one contradicts another and fragments the plan.
Orphan status or an expedited pathway in one region strengthens the case in another. We pursue them as one set, not as isolated paperwork.
After the majors approve, the economics depend on how efficiently the next markets follow. Reliance procedures compress that tail when the dossier was built for it.
Every agency hears the same story, sequenced in the order that helps you — one campaign, not parallel errands.
We lead the global function, or reset it fast when a rejection or diverging advice breaks the original plan.
Most companies need global regulatory leadership years before they can justify the full-time hire. Our senior consultants step in as acting heads of regulatory affairs, setting the strategy and running the function until you are ready to own it.
A Complete Response Letter, a failed endpoint, diverging advice between two major agencies: every global program eventually hits an event the original plan did not price in. We rebuild the strategy fast and get you filing again.
Global strategy is learned by having coordinated it, agency by agency, region by region. Your leads are senior regulatory practitioners who have taken programs through the FDA, the EMA, and the reliance markets beyond, and reconciled the contradictions between them into one plan.
Fluent across FDA, EMA, PMDA, and the reliance authorities, so the regions are coordinated rather than colliding.
We decide the order of the waves deliberately, because the first filing sets the reference for everything after it.
A single controlled core with clean regional layers, so thirty markets never quietly diverge.
The global plan presented to a board and defended under a partner's diligence, because we have built the programs that diligence examines.
A global strategy is assembled from regional programs and the submissions that carry them. These are the services it draws on most.
The US reference filing that so often anchors the global sequence, led by people who have signed the form.
Explore FDA →The route into Europe, from the centralised procedure to the post-Brexit UK and Swiss filings.
Explore Europe →The core dossier assembled and transmitted through every regional gateway, the way each authority expects.
Explore Publishing →Tell us where the program stands: markets under consideration, advice already received, and the next milestone on the calendar. We'll match you with a senior global strategy lead and respond within one business day. All inquiries are strictly confidential.
